TriangleSacituzumab govitecan-hziy (NCT06248515)
Sacituzumab govitecan-hziy trial for Thymoma (NCT06248515). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with advanced thymoma or thymic carcinoma that progressed after at least one systemic treatment. Measurable disease is required. Archived or fresh tumor tissue is requested, with an exception when unavailable and unsafe to obtain.
The idea: sacituzumab govitecan carries the DNA-damaging drug SN-38 to cells bearing TROP2. Participants receive ten milligrams per kilogram intravenously on days one and eight of 21-day cycles. Researchers measure tumor responses and side effects.
This phase 2 study plans 18 patients. Georgetown’s Chul Kim leads it; four US sites are recruiting, including Washington.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.